clinical trial · NCT05827068
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
ModernaTX, Inc.·phase2·completed·n = 698
Seasonal InfluenzamRNA-1011.1mRNA-1011.2mRNA-1012.1mRNA-1010mRNA-1010.2mRNA-1010.3
brief summary
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.
started
Mar 27, 2023
primary completion
Nov 20, 2023
completion
Nov 20, 2023
last updated
Feb 3, 2025
official title
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol